NCT05940844 2025-04-09Study of OB-002 in Patients With Refractory Metastatic CancerOrion Biotechnology Polska Sp. z o.o.Phase 1 Withdrawn
NCT04158700 2020-02-19A Study of LY3200882 and Pembrolizumab in Participants With Advanced CancerEli Lilly and CompanyPhase 1/2 Withdrawn